Cahit BİLGİN, Abidin ŞEHİTOĞULLARI, Halit DEMİR, Fuat SAYIR, Mehmet ASLAN, Ufuk ÇOBANOĞLU

Özofagusun skuamöz hücreli karsinomu olan hastalarda serum prolidaz aktivitesi, total oksidan/antioksidan ve nitrik oksit düzeyleri

Amaç: Bu çalışmada özofagusun skuamöz hücreli karsinomu olan hastalarda prolidaz aktivitesi, nitrik oksit düzeyleri ve oksidatif durum değerlendirildi. Çalışma planı: Çalışmaya özofagusun skuamöz hücreli karsinomu olan 30 hasta (11 erkek, 19 kadın; ort. yaş 61±3 yıl; dağılım, 28-77 yıl) ve 30 sağlıklı kontrol (10 erkek, 20 kadın; ort. yaş 58±5 yıl; dağılım, 31-73 yıl) dahil edildi. Serum prolidaz aktivitesi, total antioksidan kapasitesi, total oksidan durumu ve nitrik oksit düzeyleri ölçüldü. Ayrıca, oksidatif stres indeksi hesaplandı. Bulgular: Hasta grubunda belirgin şekilde artmış serum prolidaz aktivitesi, oksidatif stres indeksi değerleri, total oksidan durumu ve nitrik oksit düzeyleri saptandı (p

Serum prolidase activity, total oxidant/antioxidant, and nitric oxide levels in patients with esophageal squamous cell carcinoma

Background: This study aims to assess the prolidase activity,nitric oxide levels, and oxidative status in patients with esophagealsquamous cell carcinoma.Methods: The study included 30 patients with esophagealsquamous cell carcinoma (11 males, 19 females;mean age 61±3 years; range, 28 to 77 years) and 30 healthycontrols (10 males, 20 females; mean age 58±5 years;range, 31 to 73 years). Serum prolidase activity, total antioxidantcapacity, total oxidant status, and nitric oxide levels weremeasured. In addition, the oxidative stress index was calculated.Results: Prominently elevated serum prolidase activity, oxidativestress index values, total oxidant status, and nitric oxide levelswere detected in the patient group (p

PDF

___

1. Kuwano H, Nakajima M, Miyazaki T, Kato H. Distinctive clinicopathological characteristics in esophageal squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2003;9:6-13.
2. Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, et al. Oesophageal cancer. Nat Rev Dis Primers 2017;3:17048.
3. Chow CK. Cigarette smoking and oxidative damage in the lung. Ann N Y Acad Sci. 1993;686:289-98.
4. Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida R, Yoshinaga K, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol 2010;15:126-34.
5. Kubo N, Morita M, Nakashima Y, Kitao H, Egashira A, Saeki H, et al. Oxidative DNA damage in human esophageal cancer: clinicopathological analysis of 8-hydroxydeoxyguanosine and its repair enzyme. Dis Esophagus 2014;27:285-93.
6. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34.
7. Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol 2013;11:118.
8. Surazynski A, Liu Y, Miltyk W, Phang JM. Nitric oxide regulates prolidase activity by serine/threonine phosphorylation. J Cell Biochem 2005;96:1086-94.
9. Aslan M, Duzenli U, Esen R, Soyoral YU. Serum prolidase enzyme activity in obese subjects and its relationship with oxidative stress markers. Clin Chim Acta 2017;473:186-90.
10. Surazynski A, Donald SP, Cooper SK, Whiteside MA, Salnikow K, Liu Y, et al. Extracellular matrix and HIF-1 signaling: the role of prolidase. Int J Cancer. 2008;122:1435-40.
11. Celik S, Kızıltan R, Yılmaz EM, Yılmaz Ö, Demir H. Potential diagnostic and prognostic significance of plasma prolidase activity in gastric cancer. Biomark Med 2017;11:319-27.
12. Bayhan Z, Zeren S, Kocak C, Kocak FE, Duzgun SA, Algin MC, et al. Prolidase activity and oxidative stress in patients with breast carcinoma A prospective randomized casecontrolled study. Ann Ital Chir 2016;87:517-24.
13. Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Aksoy N. Assessment of preoperative serum prolidase activity in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2009;147:97-100.
14. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37:277-85.
15. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-11.
16. Myara I, Stalder JF. Plasma prolidase and prolinase activity in prolidase deficiency. Clin Chem 1986;32:562.
17. Tracey WR, Tse J, Carter G. Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther 1995;272:1011-5.
18. Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev 2013;12:376-90.
19. Feng JF, Lu L, Zeng P, Yang YH, Luo J, Yang YW, et al. Serum total oxidant/antioxidant status and trace element levels in breast cancer patients. Int J Clin Oncol 2012;17:575-83.
20. Wang D, Feng JF, Zeng P, Yang YH, Luo J, Yang YW. Total oxidant/antioxidant status in sera of patients with thyroid cancers. Endocr Relat Cancer 2011;18:773-82.
21. Huang Q, Feng J, Wu R, Yang Y, Dai C, Li J, et al. Total Oxidant/Antioxidant Status in Sera of Patients with Esophageal Cancer. Med Sci Monit 2017;23:3789-94.
22. Sharma A, Rajappa M, Saxena A, Sharma M. Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation. Br J Biomed Sci 2007;64:23-7.
23. Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther 2004;3:333-41.
24. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker? Free Radic Biol Med 2002;32:968-74.
25. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128-37.
26. Guszczyn T, Sobolewski K. Deregulation of collagen metabolism in human stomach cancer. Pathobiology 2004;71:308-13.
27. Cechowska-Pasko M, Pałka J, Wojtukiewicz MZ. Enhanced prolidase activity and decreased collagen content in breast cancer tissue. Int J Exp Pathol 2006;87:289-96.
28. Eijan AM, Davel LE, Rueda HA, Rozenberg G, De Lustig ES, Jasnis MA. Differential nitric oxide release and sensitivity to injury in different murine mammary tumor cell lines Int J Mol Med 1998;2:625-30.
29. Mandal P. Insight of nitric oxide signaling: A potential biomarker with multifaceted complex mechanism in colorectal carcinogenesis. Biochem Biophys Res Commun 2018;495:1766-8.
30. de Oliveira GA, Cheng RYS, Ridnour LA, Basudhar D, Somasundaram V, McVicar DW, et al. Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers. Antioxid Redox Signal 2017;26:1059-77.
31. Stoner GD, Wang LS. Chemoprevention of esophageal squamous cell carcinoma with berries. Top Curr Chem 2013;329:1-20.
32. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998;90:587-96.
33. Eiján AM, Piccardo I, Riveros MD, Sandes EO, Porcella H, Jasnis MA, et al. Nitric oxide in patients with transitional bladder cancer. J Surg Oncol 2002;81:203-8.
34. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros- Moreno V, Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994;54:1352-4.
35. Prestidge BR, Kaplan I, Cox RS, Bagshaw MA. The clinical significance of a positive post-irradiation prostatic biopsy without metastases. Int J Radiat Oncol Biol Phys 1992;24:403-8.